162 results on '"Mastey, Vera"'
Search Results
2. Effectiveness of Subcutaneous Casirivimab and Imdevimab in Ambulatory Patients with COVID-19
3. The Patient Matters in the End(point)
4. Development and content validation of the Symptoms Evolution of COVID-19: a patient-reported electronic daily diary in clinical and real-world studies
5. A novel patient-reported outcomes instrument assessing the side effects of peanut oral immunotherapy
6. Real-world persistence with dupilumab among adults with atopic dermatitis
7. Correction to: The Patient Matters in the End(point)
8. PB2281: TRIAL IN PROGRESS: FOLLICULAR LYMPHOMA OUTCOMES IN RELAPSED/REFRACTORY PATIENTS TREATED WITH SYSTEMIC THERAPY IN A REAL-WORLD ASSESSMENT (FLORA)
9. PB2357: TRIAL IN PROGRESS: OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH SYSTEMIC THERAPY FROM REAL-WORLD EXPERIENCE (ORCHID)
10. Effectively Leveraging RWD for External Controls: A Systematic Literature Review of Regulatory & HTA Decisions
11. Regulatory and HTA Considerations for Development of Real‐World Data Derived External Controls
12. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
13. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
14. Effectively Leveraging RWD for External Controls: A Systematic Literature Review of Regulatory and HTA Decisions.
15. Real-world effectiveness of casirivimab and imdevimab among patients diagnosed with COVID-19 in the ambulatory setting: a retrospective cohort study using a large claims database
16. Trial in Progress: Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Systemic Therapy from Real-World Experience (ORCHID)
17. Trial in Progress: Follicular Lymphoma Outcomes in Relapsed/Refractory Patients Treated with Systemic Therapy in a Real-World Assessment (FLORA)
18. Patient‐reported outcomes with cemiplimab monotherapy for first‐line treatment of advanced non–small cell lung cancer with PD‐L1 of ≥50%: The EMPOWER‐Lung 1 study
19. Reliability and Validity of an Instrument of COVID-19 Patient-Reported Symptoms in Outpatients
20. Patient-reported outcomes labeling for oncology drugs: Multidisciplinary perspectives on current status and future directions
21. Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults
22. Effectiveness of Subcutaneous Casirivimab and Imdevimab Relative to no COVID-19 Antibody Treatment Among Patients Diagnosed With COVID-19 in the Ambulatory Setting
23. Patient experience of symptoms and impacts of COVID-19: a qualitative investigation with symptomatic outpatients
24. Patient‐reported outcomes with cemiplimab monotherapy for first‐line treatment of advanced non–small cell lung cancer with PD‐L1 of ≥50%: The EMPOWER‐Lung 1 study.
25. Real-world Effectiveness of Casirivimab and Imdevimab in Patients With COVID-19 in the Ambulatory Setting: An Analysis of Two Large US National Claims Databases
26. Effects of Copayment on Initiation of Smoking Cessation Pharmacotherapy: An Analysis of Varenicline Reversed Claims
27. A reliable and valid measure of COVID-19 patient-reported symptoms in outpatients: the Symptoms Evolution of COVID-19 (SE-C19) instrument
28. Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults
29. Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis
30. Development and Content Validation of the Symptoms Evolution of COVID-19: A Patient-Reported Electronic Daily Diary in Clinical and Real-World Studies
31. Health-related quality of life (HRQoL) in patients (pts) with locally advanced basal cell carcinoma (laBCC) treated with cemiplimab: Analysis of a phase II, open-label clinical trial
32. The patient experience of COVID-19: A qualitative investigation with symptomatic outpatients
33. Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 ≥ 50%: Results from EMPOWER-Lung 1 study.
34. Health-related quality of life (HRQoL) in patients (pts) with locally advanced basal cell carcinoma (laBCC) treated with cemiplimab: Analysis of a phase II, open-label clinical trial.
35. Cemiplimab Improves Health-Related Quality of Life (HRQoL) and Reduces Pain in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Results from a Post Hoc Exploratory Analysis of a Phase 2 Clinical Trial
36. Health-Related Quality of Life (HRQL) in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC) Treated with Cemiplimab: Post Hoc Exploratory Analysis of a Phase 2 Clinical Trial
37. Health-related quality of life (HRQL) in patients with advanced cutaneous squamous cell carcinoma (CSCC) treated with cemiplimab: Post hoc exploratory analyses of a phase II clinical trial.
38. Donepezil Is Associated with Delayed Nursing Home Placement in Patients with Alzheimerʼs Disease
39. Efficacy of Donepezil on Maintenance of Activities of Daily Living in Patients with Moderate to Severe Alzheimerʼs Disease and the Effect on Caregiver Burden
40. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2
41. Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma
42. Recent trends in exposure to secondhand smoke in the United States population
43. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2.
44. Association of Inadequately Controlled Disease and Disease Severity With Patient-Reported Disease Burden in Adults With Atopic Dermatitis
45. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
46. Cost-effectiveness of PCSK9 Inhibitor Therapy
47. Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)
48. Dupilumab improves patient-reported outcomes in chronic sinusitis with nasal polyps patients with comorbid asthma: Results from a phase 2a trial
49. Dupilumab reduces severe exacerbation-related costs among asthma patients: Results from a phase 2b trial
50. Burden of Persistent Asthma in Patients Treated With Medium- to High-Dose Inhaled Corticosteroids: Baseline Data From a Phase 2 Clinical Trial of Dupilumab
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.